MedPath

Effect of herbal drug Terminalia chebula, Commiphora myrrh and Commiphora mukul mixture on diabetes in patients with hyperlipidemia .

Phase 2
Conditions
Condition 1: Diabetes. Condition 2: Added at 2015-07-20: Mixed hyperlipidaemia.
Non-insulin-dependent diabetes mellitus
Added at 2015-07-20: Hypercholesterolaemia with endogenous hyperglyceridaemia and Hyperlipidaemia, group C
E10, E14,
Added at 2
Registration Number
IRCT201307011157N8
Lead Sponsor
Vice chancellor for research, Institute of Medicinal Plants
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Iranian type 2 diabetic patients; aged 40 to 60 years; fasting blood glucose levels from 150 to 180 mg/dL; blood glycosylated hemoglobin levels from 7.5 to 8.5 percent; LDL-c > 100 mg/dL; triglyceride >150 mg/dL; oral intake of not more than 10 mg glyburide and 1000 mg metformin at maximum. Exclusion criteria: Patients receiving insulin therapy; patients with cardiao vascular, renal, hepatic, hematological, hypothyroidism, vertigo and seizure diseases; patients with a history of gallstones or gall bladder surgery; patients under estrogen, steroid, beta-blocker and thiazide therapy; pregnant women; women planning for pregnancy; breast-feeding women.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercial standard kit.;Glycosylated hemoglobin (HbA1c). Timepoint: At starting of the study and after 3 months. Method of measurement: HbA1c percent will be determined in laboratory by commercial standard kit.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath